SeqOnce Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- SeqOnce Biosciences's estimated annual revenue is currently $2.3M per year.
- SeqOnce Biosciences's estimated revenue per employee is $155,000
Employee Data
- SeqOnce Biosciences has 15 Employees.
- SeqOnce Biosciences grew their employee count by -17% last year.
SeqOnce Biosciences's People
Name | Title | Email/Phone |
---|---|---|
1 | President & CEO | Co-Founder | Reveal Email/Phone |
SeqOnce Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is SeqOnce Biosciences?
SeqOnce Biosciences is a privately held company located in Pasadena, California. Our core competencies, including enzymology, nucleic acid chemistry, sample processing and manufacturing, have served as engines for innovation, development of intellectual property, and ongoing product development. SeqOnce Biosciences was formed in 2014 by Joseph Dunham, Ph.D, a researcher at the University of Southern California and Chris Angermayer, a former portfolio manager and investment analyst. The founders are dedicated to building a team of individuals who are leaders in the industry, thereby enabling SeqOnce to become a preeminent player in the NGS sample preparation market.
keywords:N/AN/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.2M | 15 | -32% | N/A |
#2 | $1.3M | 15 | 7% | N/A |
#3 | $2.3M | 15 | 15% | N/A |
#4 | $1.7M | 15 | -12% | N/A |
#5 | $2.6M | 15 | -42% | N/A |